Home » Stocks » CBLI

Cleveland BioLabs, Inc. (CBLI)

Stock Price: $2.77 USD 0.09 (3.36%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 36.06M
Revenue (ttm) 857,832
Net Income (ttm) -2.12M
Shares Out 13.02M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $2.77
Previous Close $2.68
Change ($) 0.09
Change (%) 3.36%
Day's Open 2.63
Day's Range 2.60 - 3.21
Day's Volume 1,758,194
52-Week Range 0.50 - 5.43

More Stats

Market Cap 36.06M
Enterprise Value 32.29M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 13.02M
Float 5.67M
EPS (basic) -0.18
EPS (diluted) -0.18
FCF / Share -0.17
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 172,740
Short Ratio 1.86
Short % of Float 3.04%
Beta 0.71
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 42.03
PB Ratio n/a
Revenue 857,832
Operating Income -1.84M
Net Income -2.12M
Free Cash Flow -1.97M
Net Cash 3.77M
Net Cash / Share 0.29
Gross Margin -63.30%
Operating Margin -213.98%
Profit Margin -246.60%
FCF Margin -229.43%
ROA -32.02%
ROE -78.98%
ROIC 2,331.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $2.77
Target: 40.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-2.18%-41.58%-44.62%29.92%-26.84%-56.39%137.71%-59.38%-42.67%-
Gross Profit1.111.141.953.522.713.708.493.578.7915.33
Operating Income-2.36-4.80-5.60-6.36-10.79-14.42-23.08-30.05-25.11-10.74
Net Income-2.65-3.61-9.71-2.66-12.641.63-17.26-18.23-4.01-26.37
Shares Outstanding11.3011.2911.1910.997.062.702.251.871.631.31
Earnings Per Share-0.23-0.32-0.87-0.24-1.790.60-7.67-9.75-2.40-20.20
Operating Cash Flow-2.66-4.61-6.61-5.04-12.08-14.46-23.10-20.65-16.91-5.90
Capital Expenditures0.050.01-0.190.01-0.02-0.14-0.18-0.66-0.47
Free Cash Flow-2.61-4.61-6.61-4.85-12.07-14.48-23.24-20.83-17.56-6.36
Cash & Equivalents1.584.128.7915.2519.664.8013.2829.8628.3911.38
Total Debt-----4.157.560.17--
Net Cash / Debt1.584.128.7915.2519.660.665.7129.6928.3911.38
Book Value-4.06-1.452.207.529.89-1.61-9.526.339.06-15.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cleveland BioLabs, Inc.
Country United States
Employees 7
CEO Christopher Zosh

Stock Information

Ticker Symbol CBLI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CBLI
IPO Date July 21, 2006


Cleveland BioLabs, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.